SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is surging above $71,000, igniting community excitement and signaling a potential end to recent downtrends as many anticipate a new bull phase and the liquidation of short positions. The rally is supported by ongoing conversations around proposed crypto legislation, with prominent figures criticizing banks for hindering market progress, and some investors increasingly viewing Bitcoin as a resilient asset amidst global uncertainty.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is gaining significant traction following a definitive commercial agreement and strategic investment from TELUS, reinforcing its commercial validation and financial runway. The community is overwhelmingly bullish on the company's strong earnings, projecting substantial revenue growth and accelerating satellite deployment, particularly as it displays remarkable strength amidst a challenging market.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amidst surging crude oil prices driven by escalating Middle East tensions and threats to the Strait of Hormuz, sparking intense community debate as the stock experiences a sharp sell-off. Investors are questioning potential market manipulation or dilution, while others anticipate a significant rebound due to its low float and high short interest.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending as a highly leveraged bet on Bitcoin's price movements, with community sentiment sharply divided. Bulls are actively discussing the potential for a significant short squeeze as MSTR continues its strategy of acquiring more BTC, while bears express concern over ongoing share dilution and the company's valuation.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as reports indicate major automakers are exiting its EU carbon credit pool, potentially impacting a revenue stream, while Elon Musk's ambitious push into AI and humanoid robotics sparks intense community debate over the company's future direction amidst broader market volatility.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending sharply upward after its robust Q4 earnings reported significant growth in USDC circulation and profitability, fueling a massive short squeeze. The community is buzzing about its foundational role in AI agentic commerce and its potential to benefit from both favorable stablecoin regulation and persistent interest rate levels.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending due to its announced strategic partnership with Starwood Capital to develop AI/HPC data centers, a significant pivot from pure Bitcoin mining that is sparking fervent debate among investors. Despite a substantial Q4 net loss driven by Bitcoin write-downs, the community is weighing this diversification as a potential long-term value driver against concerns about execution and market timing.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid high anticipation for its upcoming earnings, as the community fiercely debates its valuation and strategic position in the evolving Agentic AI landscape. Investors are polarized between those highlighting its strong balance sheet, institutional ownership, and role as an AI orchestration platform, and those concerned about competition and recent price weakness, fueling speculation of a potential short squeeze.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending as its dedicated community champions extensive real-world brand building through initiatives like KENDU SPICE and energy drinks, coupled with its verified token presence across Ethereum and Base. Members are actively engaged in dollar-cost averaging and showcasing strong conviction in the project's long-term vision, distinguishing it as a brand-focused entity in the crypto space.

Wix.com Ltd. engages in providing a web development platform for creators, delivering its solutions through a Software-as-a-Service model. Its products include website templates, website builder, website design, Wix features, app market, web hosting, domain names, website accessibility, mobile app builder, and AI website builder. The company was founded by Avishai Abrahami, Nadav Abrahami, Nir Zohar, and Giora Kaplan on October 5, 2006 and is headquartered in Tel Aviv, Israel.

Wix.com Ltd

Wix is trending after a mixed earnings report that saw an EPS beat offset by a revenue miss, fueling community debate. Investors are actively discussing the company's substantial share repurchase program, robust free cash flow, and strategic AI integrations like Base44 and Harmony as potential catalysts, while also weighing concerns about broader AI disruption in the web development space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel, Jan...

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH Galmed Announces Grant of New Use Patents for the combination...

Galmed Issues CEO Letter to Shareholders

Galmed Issues CEO Letter to Shareholders Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel, Dec. 1, 2025 TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd...

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire RAMAT-GAN...

<ul class="summary-bullets"><li>Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.</li><li>The company plans to begin Phase 1b trials in early 2026 as key Stivarga patents near expiration.</li><li>Stocktwits users focused on possible dilution, SEC filings, and the timing of upcoming earnings.</li></ul>Galmed Pharmaceuticals shares&nbsp;rose on Monday, following four sessions of losses, after the company reported top-line results showing that a three-drug combination of Aramchol, Stivarga and Metformin significantly improved tumor-cell killing in gastrointestinal cancers.The stock closed up 1% at $1.05 before slipping 4.6% in after-hours trading.<h2 class="st-heading-2">Top-Line Results Highlight Triple-Drug Effect</h2>Galmed said the regimen of Aramchol, Stivarga and Metformin demonstrated a significant synergistic effect, improving tumor-cell killing both in vivo and in vitro. The company said the combination&nbsp;could be developed as a fixed-dose therapy that could strengthen the effect of Stivarga, Bayer’s top-selling cancer drug.According to the company, the combination may serve as a life-cycle IP strategy for Stivarga as key patents expire in Europe in August 2028 and in the U.S. in July 2032. Two new U.S. patent applications have been submitted.Galmed said the Aramchol-Stivarga combination is expected to enter Phase 1b clinical trials in early 2026 for metastatic colorectal cancer, hepatocellular carcinoma and cholangiocarcinoma, with a planned expansion cohort including Metformin.<h2 class="st-heading-2">Study Builds On Prior Findings</h2>An earlier May study reported that Aramchol enhanced the efficacy of regorafenib in gastrointestinal cancer models. In that study, Aramchol&nbsp;enhanced the breakdown of cellular material triggered by regorafenib and affected several cell-signaling pathways linked to tumor growth. The combination also reduced tumor growth in liver cancer models without harming normal tissue.The newly announced results include additional data on&nbsp;the use of Aramchol in combination with regorafenib and Metformin. The study reported that Aramchol showed anti-tumor activity on its own and when&nbsp;combined with the other two drugs, and that the three-drug combination produced a reinforcing effect, supporting further development as a combined treatment.<h2 class="st-heading-2">Clinical Path Ahead</h2>Allen Baharaff said a fixed-dose combination with Aramchol “could potentially become a life-cycle IP strategy for regorafenib to help delay the generic competition.”Baharaff said the company is preparing to initiate its Phase 1b study at VCU Massey Comprehensive Cancer Center in early 2026. He added that positive findings could support accelerated development of Aramchol across three gastrointestinal cancer indications and expand the company’s pipeline.<h2 class="st-heading-2">Stocktwits Users Flag Possible Dilution</h2>On Stocktwits, retail sentiment for Galmed was ‘extremely bullish’ amid a 12,950% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/glmd_ss_jpg_a183d03fe6.webp" alt="glmd ss.jpg" width="968" height="143"><figcaption>GLMD sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure>One user said, “Now let's wait for SEC filing. Crossed my fingers. I will tell you, if no dilution SEC is filed today after market close or before market opens, then get ready for another run and this would be epic run”<stembedurl>https://stocktwits.com/madan_shatri/message/636516948</stembedurl>Another user commented that they anticipated earnings “any day” and suggested the stock might attempt “a runup” before a potential offering.<stembedurl>https://stocktwits.com/Jonsie/message/636511939</stembedurl>Galmed’s stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Galmed Pharmaceuticals logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks

Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.

Equity

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro Galmed...

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Pharmaceuticals (GLMD) shares rose sharply on Tuesday after the company reported positive preclinical data showing that its experimental drug Aramchol enhances the effectiveness of Regorafenib in liver and colon cancer models.Following the announcement, Galmed's stock rose by 10.6%, closing at $1.46 per share.&nbsp;According to the company, Aramchol improved the anti-tumor activity of Regorafenib — a multi-kinase inhibitor approved for liver and colorectal cancers — in both in-vitro and in-vivo settings.&nbsp;The combination also activated ATM and AMPK pathways while inhibiting mTORC1 and mTORC2, mechanisms known to play roles in cancer cell survival.Aramchol was also shown to work in combination with other kinase inhibitors like Sorafenib and Lenvatinib, though Regorafenib exhibited the strongest synergistic effects.&nbsp;The dual treatment suppressed tumor growth in hepatoma models without causing toxicity to normal tissues, the company said.Retail sentiment spiked following the update.&nbsp;On Stocktwits, message volume surged 4,480% over 24 hours, with sentiment marked as ‘extremely bullish.’Some retail investors suggested the stock could double from a previous $1.31 entry level.&nbsp;<stembedurl>https://stocktwits.com/debbiekatz/message/613719065</stembedurl>Others speculated the price could climb to the $2.50–$3.00 range, reflecting confidence ahead of the next trading session.<stembedurl>https://stocktwits.com/ZCOCSTOCK/message/613738896</stembedurl>Galmed said it expects to initiate a Phase 1b trial of Aramchol in combination with Regorafenib by the fourth quarter of 2025.The oncology update comes on the heels of another strategic development.&nbsp;Last week, Galmed signed a binding term sheet with Entomus s.r.o. for the licensing of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation.&nbsp;The technology enables sublingual absorption of peptides such as GLP-1, a key target in metabolic disorders.&nbsp;A definitive agreement outlining milestones and royalty terms is expected within 90 days.Shares of Galmed have fallen 56% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RBC said Medicaid spending was politically harder to unwind than the Journal suggested, adding that many small and rural hospitals depend on these payments to stay afloat. | Image source: Getty Images

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

GLMD
Galmed Pharmaceuticals Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest GLMD News

GLMDGalmed Pharmaceuticals Ltd